EQT

Perfuze is a neurovascular medical device company based in Galway, Ireland, founded in 2018. The company focuses on developing innovative catheter technology specifically for the treatment of acute ischemic stroke. Perfuze aims to enhance clinical outcomes and reduce procedural times through its proprietary catheter-based aspiration technology, which optimizes the efficiency of clot removal. By simplifying procedures and minimizing the need for alternative treatment methods, Perfuze seeks to provide cost-effective solutions for patients suffering from ischemic stroke.

Cornerstone Robotics is a company dedicated to enhancing the accessibility of advanced medical services in China through the development of innovative medical robotic devices. Its primary focus lies in creating a safe and efficient surgical robotics platform that empowers physicians to perform surgeries with greater accuracy and efficiency. By investing in research and development, Cornerstone Robotics aims to advance the field of surgical robotics, thereby improving patient outcomes and transforming surgical practices.

NUA Surgical is an award-winning startup based at the Innovation Hub in Galway, Ireland. The company has developed a patented surgical retractor designed to enhance the safety and efficiency of C-section procedures. NUA Surgical focuses on creating innovative medical devices for women's health, with a particular emphasis on improving outcomes for cesarean deliveries.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Phagenesis Limited is a medical device company based in Manchester, United Kingdom, founded in 2007. It focuses on developing innovative technology to treat dysphagia, a condition often associated with stroke and brain injuries that impairs safe swallowing. The company's flagship product, Phagenyx, consists of a base station that delivers targeted electrical stimulations to patients while recording and storing their information, and a catheter that is introduced through the nose to stimulate the pharynx. This approach leverages the brain’s neuroplasticity, enabling patients to relearn essential swallowing functions that may have been lost due to brain damage. Phagenesis aims to improve the recovery process for stroke patients in acute care settings by utilizing a method developed by Prof. Shaheen Hamdy of the University of Manchester, which has been validated through publication in reputable scientific and medical journals.

Onera Health, Inc. specializes in sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, the company utilizes advanced sleep diagnostic patch systems that collect and analyze sleep data. These innovative solutions are designed to enhance patient care by providing comprehensive sleep test data to healthcare professionals across various settings, thereby improving the management of sleep-related ailments and potentially benefiting other medical fields through remote monitoring of chronic conditions. Onera Health's mission is to improve the health and quality of life for individuals struggling with sleep issues while also contributing to cost reductions in healthcare.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

SHL Medical AG specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989 and headquartered in Zug, Switzerland, the company serves pharmaceutical and biotech firms around the globe. In addition to its core product offerings, SHL Medical provides comprehensive services such as final assembly, labeling, and packaging. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring that it delivers innovative and reliable solutions tailored to meet the needs of its clients.

Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.

SPT Labtech is a manufacturer and designer of automated instrumentation and consumables for life science research. The company specializes in enhancing agility, efficiency, and productivity across various applications, including drug discovery, structural biology, molecular biology, and genomics. Its product portfolio focuses on minimizing assay volumes, streamlining workflows, and reducing material handling costs, thereby empowering life scientists to accelerate their research. SPT Labtech emphasizes collaboration and deep application knowledge, which informs its research and development efforts. The company is committed to addressing existing customer challenges through innovative solutions, driven by a strong ethos of customer-centricity. Additionally, its extensive expertise allows SPT Labtech to manage the entire life cycle of its products, from initial design and engineering to final manufacture and support, ensuring high-quality technical assistance and fostering strong client relationships.

Perfuze is a neurovascular medical device company based in Galway, Ireland, founded in 2018. The company focuses on developing innovative catheter technology specifically for the treatment of acute ischemic stroke. Perfuze aims to enhance clinical outcomes and reduce procedural times through its proprietary catheter-based aspiration technology, which optimizes the efficiency of clot removal. By simplifying procedures and minimizing the need for alternative treatment methods, Perfuze seeks to provide cost-effective solutions for patients suffering from ischemic stroke.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Icon Group is a global provider of cancer care services, focusing on delivering comprehensive care to patients at accessible locations. The company offers a range of services including medical and radiation oncology, hematology, health screening, pharmacy, chemotherapy, and compounding. By aiming to enhance the quality of care available, Icon Group ensures that patients receive tailored treatment options close to their homes, thereby improving the overall patient experience in cancer care.

Meine Radiologie Holding GmbH is a provider of radiological and radiotherapy treatment services focused on imaging diagnostics. The company specializes in offering radiology diagnostics and radiation treatments for both malignant and benign conditions. Additionally, it supports radiological and nuclear medicine practices by acting as a financial investor and professional management partner, particularly in succession planning. Through its services, Meine Radiologie Holding aims to create added value for doctors, employees, referrers, and patients by optimizing both central and local processes within the healthcare framework.

PAREXEL International Corporation is a biopharmaceutical services company that supports the pharmaceutical, biotechnology, and medical device industries globally. Founded in 1983 and headquartered in Waltham, Massachusetts, PAREXEL offers a wide range of services through three main segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics. The CRS segment specializes in managing clinical trials, including study design, patient enrollment, data management, and pharmacovigilance. The PCMS segment provides consulting services in drug development, regulatory affairs, and market access, assisting clients with product launch strategies and reimbursement issues. Additionally, the Perceptive segment offers technology solutions such as medical imaging, data management systems, and patient engagement applications. By delivering comprehensive expertise in clinical research and commercialization, PAREXEL facilitates scientific discoveries and the development of new treatments.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Neurent Medical Limited is a medical device company based in Galway, Ireland, founded in 2015 by Brian Shields and David Townley. The company specializes in developing non-surgical treatments for inflammatory sino-nasal diseases, specifically focusing on chronic rhinitis. Neurent Medical offers a single-use, minimally invasive device designed for ENT surgeons, which utilizes a hand-held radio-frequency mechanism. This device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization, where it deploys a microelectrode array to deliver targeted energy. This intervention interrupts the autonomic function of the mucosal structures in the nasal cavities, effectively reversing the inflammatory cascade. By enabling treatment in an office setting, Neurent Medical aims to eliminate the complications and costs typically associated with traditional surgical procedures for rhinitis.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

SHL Medical AG specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989 and headquartered in Zug, Switzerland, the company serves pharmaceutical and biotech firms around the globe. In addition to its core product offerings, SHL Medical provides comprehensive services such as final assembly, labeling, and packaging. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring that it delivers innovative and reliable solutions tailored to meet the needs of its clients.

Mabtech AB is a biotech company based in Stockholm, Sweden, specializing in the development and manufacture of monoclonal antibodies and diagnostic kits. Founded in 1986, the company offers a range of products for enzyme-linked immuno sorbent assay (ELISA), enzyme-linked immunospot assay (ELISpot), and FluoroSpot methods, facilitating the detection of cytokines and other immunological molecules. Mabtech's product portfolio includes monoclonal antibodies for various applications, as well as specialized kits for ELISA, ELISpot, and FluoroSpot, which allow for the simultaneous detection of multiple analytes. The company serves a diverse clientele, providing tools for research involving human and animal samples across various species. Mabtech sells its products online and has established locations in the United States, Australia, Germany, and France, operating as a subsidiary of Mabtech Group AB.

iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established itself in the field with its flagship product, the STARflo glaucoma implant. This non-degradable, precision-pore device functions as a micro-porous drainage system that reduces intraocular pressure by enhancing the eye’s natural uveoscleral outflow. iSTAR Medical's offerings also include STARflo PLUS and STARflo MINI surgical therapies, which incorporate anti-fibrotic and anti-inflammatory properties to improve patient outcomes. The company operates from its eco-friendly R&D and manufacturing facility in CREALYS Scientific Park near Namur, Belgium, and distributes its products through various international partners across Europe and Asia. iSTAR Medical is committed to providing advanced and effective treatment alternatives for glaucoma patients, with its devices designed to limit inflammation and fibrosis while promoting bio-integration with surrounding tissues.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Karo Pharma is a pharmaceutical company. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.

Zemax, LLC is a software development company based in Kirkland, Washington, specializing in optical and illumination design. Founded in 2014, Zemax provides advanced software solutions for a variety of applications, including projection lenses, binocular lenses, collimating lenses, and biomedical imaging. The company's offerings are tailored to industries such as aerospace, defense, medical and life sciences, instrumentation, optics, and lighting. Zemax's software is known for its technical capabilities, user-friendliness, and accuracy, facilitating efficient collaboration between optical and mechanical engineers. In addition to software, Zemax also offers training and support services to enhance the design process for its users.

Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Clinical Innovations is the largest healthcare manufacturer exclusively focused on labor and delivery. Already a market leader in several categories with products such as the Koala® Intrauterine Pressure Catheter and Kiwi® Vacuum-Assisted Delivery System, Clinical Innovations is expanding its global presence while directly researching and developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world. Since its inception in 1993, Clinical Innovations has consistently expanded its worldwide presence, becoming the market leader in several product categories. This growth has fueled the ability to invest in new product ideas where innovation makes the difference. And with a management team with extensive experience in the medical device industry, Clinical Innovations possesses the working knowledge to develop those new product ideas into industry-changing specialty devices. Clinical Innovations is dedicated to quality and customer service. With ISO13485 certification and strong relationships with top worldwide medical distributors, Clinical Innovations has the systems and infrastructure in place to promptly respond to market trends and customer suggestions. Clinical Innovations is a Prizker Group Company.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.

Ottobock is a designer and manufacturer of prosthetic limbs dedicated to enhancing the mobility and quality of life for individuals with disabilities. The company focuses on innovative solutions, offering products such as a computerized knee that adapts its resistance to accommodate various walking gaits, and a fully articulated robotic hand prosthesis. These advancements enable users to overcome challenges associated with their disabilities, promoting independence and active lifestyles. Driven by a commitment to innovation and the desire to provide optimal support for those in need, Ottobock strives to improve the overall well-being of its customers.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Rotation Medical Inc. is a medical technology company based in Plymouth, Minnesota, that specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant system utilizes a collagen scaffold designed to be affixed to the affected rotator cuff tendon, offering a surgical solution for managing and protecting tendon injuries. This system is particularly beneficial for patients with small rotator cuff tears and provides additional protection for those with larger tears. Founded in 2009, Rotation Medical was originally known as Denali Medical Inc. before rebranding in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Neuravi Limited, established in 2009 and based in Galway, Ireland, specializes in designing and developing medical devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries and is a subsidiary of DePuy Ireland Unlimited Company.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

Sivantos is a leading global manufacturer of hearing aids, with a strong presence in many countries. With a history of over 100 years, they have developed and manufactured one out of every four hearing aids used worldwide. Their portfolio includes well-known brands such as Siemens, Signia, Audio Service, Rexton, and A&M, along with accessories, fitting software, smartphone apps, and diagnostics workflow solutions. Employing about 5,000 people across more than 25 countries, Sivantos is dedicated to helping hearing-impaired individuals enjoy the sound of life.

Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Rotation Medical Inc. is a medical technology company based in Plymouth, Minnesota, that specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant system utilizes a collagen scaffold designed to be affixed to the affected rotator cuff tendon, offering a surgical solution for managing and protecting tendon injuries. This system is particularly beneficial for patients with small rotator cuff tears and provides additional protection for those with larger tears. Founded in 2009, Rotation Medical was originally known as Denali Medical Inc. before rebranding in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

IlluminOss Medical, Inc., established in 2007 and headquartered in East Providence, Rhode Island, is a medical device company specializing in orthopedic fracture repair. It designs, develops, and markets products based on its proprietary IlluminOss System, which employs a light-curable polymer within an expandable balloon catheter to create patient-specific intramedullary implants for bone stabilization. This minimally invasive technology is particularly suited for treating osteoporotic and compromised bone. The company's products are CE-marked and FDA-cleared for various anatomical sites and are distributed in several European countries.

BSN medical is a global leader in the healthcare market, specializing in compression therapy, wound care, and orthopedics. Based in Luxembourg, the company manufactures a range of medical products designed to provide effective solutions for caregivers and patients. Its offerings focus on the treatment of acute, chronic, and hard-to-heal wounds, ensuring a seamless progression of therapy. BSN medical integrates strong technological competencies with a broad portfolio in wound care, vascular diseases, and non-invasive orthopedics, addressing the need for simplified and efficient treatment options. The company is committed to developing high-quality branded products that support a comprehensive continuum of care.

Atos Medical, founded in 1986, specializes in manufacturing therapeutic devices aimed at enhancing the quality of life for laryngectomized patients. The company produces a range of products, including voice prosthetics, pulmonary rehabilitation devices, adhesives, laryngectomy tubes, and hands-free speaking devices. With its headquarters in Sweden, Atos Medical operates a state-of-the-art clean room and laboratory to support research and development. The company has established a significant international presence, with subsidiaries in multiple countries, including the USA, UK, Germany, Spain, the Netherlands, Belgium, Sweden, and Switzerland, along with exclusive distributors in around 60 countries.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Mendor is a Finnish company focused on the design, development, and marketing of advanced diabetes management products. It has introduced an innovative all-in-one blood glucose meter and a web-based software application that simplify daily diabetes management. These products are developed in collaboration with users and diabetes experts, ensuring they meet the specific needs of individuals requiring regular blood glucose monitoring. Mendor's patented software systems deliver real-time diabetes care data, enhancing the efficiency and effectiveness of treatment for patients and caregivers alike.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, Sapiens operates from offices in Eindhoven, the Netherlands, and Munich, Germany. The company is dedicated to developing a high-resolution, MRI-compatible DBS system designed to enhance patient comfort and improve therapeutic outcomes, particularly for individuals with Parkinson's disease. Sapiens’ innovative approach includes a unique steering brain stimulation system and image-guided programming, both of which are based on patented technologies.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

Activaero GmbH is a drug delivery company specializing in controlled breathing technologies designed for the pulmonary delivery of inhaled therapeutic agents. Founded in 2004 and based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero develops innovative devices such as AKITA, which utilizes smart card technology for efficient drug delivery, and Watchhaler, specifically designed for children requiring inhaled medication. The company also offers AKITA², a technology for use in clinical trials, and LimiX, a flow limitation valve that regulates inhalation flow rates. In addition to its product offerings, Activaero provides measurement and diagnostic technologies for laboratory applications, including aerosol property measurement systems. Furthermore, the company engages in contract development and clinical trial logistics services, marketing its products through a network of distributors. Activaero's solutions aim to improve therapy outcomes for patients suffering from severe respiratory diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis.

Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, the company has developed the SmartFocus technology, which utilizes navigated transcranial magnetic stimulation (TMS) with 3D navigation for precise targeting of brain areas. Nexstim's product offerings include the NBT system, designed for treating major depressive disorder and chronic neuropathic pain, and the NBS system, used for pre-surgical mapping of the speech and motor cortices. The NBS systems are primarily sold to universities and teaching hospitals. Nexstim operates in various markets, including Finland, Europe, and North America, with a significant portion of its revenue generated in North America. The company's commitment lies in addressing significant unmet clinical needs and improving the quality of life for patients.

Roeser Group, based in Essen, Germany, is a supplier and distributor of medical products and equipment, primarily serving hospitals. Founded in 1918, the company offers a wide range of medical supplies, including syringes, cannulae, catheters, drainage systems, sterile packaging, and various operating instruments. In addition to its role as a manufacturer and neutral distributor, Roeser Group provides consulting, logistics, and procurement services through its subsidiaries, enhancing its value-added offerings to the healthcare sector. The company is a subsidiary of Sana Kliniken AG since May 2018.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

HTL-Strefa is the globally unrivalled, leading developer and provider of blood micro-sampling medical devices with a 44% global market share by volume in safety lancets, with a strong and growing global position in personal lancets and pen needles.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

SFC Koenig specializes in high-quality sealing and flow control technology, offering a diverse range of products and reliable solutions tailored for both standard and customized applications. The company manufactures products designed to deliver precise sealing, flow control, and regulation, ensuring compliance with stringent safety and environmental standards. SFC Koenig's solutions enhance system reliability and efficiency while minimizing the risk of component damage. Additionally, the company focuses on reducing waste in the supply chain and lowering lifecycle costs, producing components with optimized total production costs. Its product portfolio includes fastening and sealing technology, force-fitting fasteners, rivet systems, screw threads, adhesive products, and related automation services, serving various industries such as automotive, aerospace, medical engineering, electronics, transportation, and construction.

Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, the company has developed the SmartFocus technology, which utilizes navigated transcranial magnetic stimulation (TMS) with 3D navigation for precise targeting of brain areas. Nexstim's product offerings include the NBT system, designed for treating major depressive disorder and chronic neuropathic pain, and the NBS system, used for pre-surgical mapping of the speech and motor cortices. The NBS systems are primarily sold to universities and teaching hospitals. Nexstim operates in various markets, including Finland, Europe, and North America, with a significant portion of its revenue generated in North America. The company's commitment lies in addressing significant unmet clinical needs and improving the quality of life for patients.

FlowCardia, Inc. is a medical device company established in 2002 that specializes in developing innovative catheter-based technologies aimed at facilitating guidewire crossing of chronic total occlusions (CTOs) in both coronary and peripheral arteries. CTOs pose significant challenges in interventional therapy, often leading to patients being referred for more invasive procedures such as bypass surgery or limb amputation due to the lack of effective recanalization devices. FlowCardia is dedicated to addressing this critical need within the medical community by providing advanced solutions that enhance the safety and efficacy of CTO recanalization.

ISTO Technologies, Inc., an orthobiologics company, develops biologic products to regenerate and restore function to damaged cartilage and bone. It offers InQu, a resorbable bone graft extender and substitute; NuQu, a cell-based injectable therapy for disc regeneration; and DeNovo ET, an engineered cartilage implant for the repair and regeneration of knee cartilage. The company provides its products through distributors. ISTO Technologies, Inc. was founded in 1997 and is based in St. Louis, Missouri.

Okairos AG is a biopharmaceutical company headquartered in Basel, Switzerland, with operations in Rome and Naples, Italy. The company specializes in the discovery and development of genetic T-cell vaccines, focusing on conditions such as hepatitis C virus. Okairos also excels in gene delivery technologies, providing expertise in scalable viral-vector manufacturing processes. This enables other biotech firms to transition genetic vaccines and medicinal products from preclinical stages to commercial readiness, utilizing advanced good manufacturing practice (GMP) facilities. Previously a subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Okairos is dedicated to advancing innovative therapeutic solutions in the healthcare sector.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

Gambro is a global medical technology company specializing in the development, manufacturing, and supply of products and therapies for kidney and liver dialysis, as well as other extracorporeal treatments for chronic and acute patients. Founded in 1964, Gambro has been a pioneer in dialysis technology, which is critical for patients suffering from organ failure, particularly since kidney transplantation is often not a viable option due to donor shortages. The company innovates in various areas, including hemodialysis, peritoneal dialysis, renal intensive care, and hepatic care, providing solutions that enhance treatment quality and efficiency in clinics and intensive care units. With around 8,000 employees, Gambro operates 13 production facilities across multiple countries and has a presence in more than 90 countries worldwide, demonstrating its commitment to improving patient care through advanced medical technologies.

KaVo Kerr Group is a prominent organization in the dental industry, formed by the merger of two global leaders committed to delivering dental excellence. With a history spanning over 100 years, KaVo has established a strong reputation for innovation and quality in dental products and services, catering to the needs of dentists, dental technicians, and hygienists. The company provides a comprehensive range of products, including imaging systems, treatment units, instrumentation, laboratory equipment, and educational aids. KaVo is recognized for its advanced analog and digital dental imaging solutions, which include intra-oral and extra-oral X-ray applications available through its brands such as Soredex and Instrumentarium Dental. This dedication to product development, service, and support underscores KaVo Kerr's commitment to enhancing dental care worldwide.

Palodex is a manufacturer of dental imaging products.

Carl Zeiss Vision Holding, established in 2005, is a leading manufacturer of ophthalmic products. The company specializes in designing, producing, and distributing high-quality spectacle lenses, along with associated diagnostic tools, services, and business support for eyecare professionals. Its product portfolio includes various lens designs, coatings, and materials, with a focus on organic lenses, catering to the growing demand in the market.

Metall Technologie Holding is a German manufacturer specializing in heat treatment industrial furnaces and related technologies. The company produces a variety of furnace types, including vacuum furnaces, continuous furnaces, atmosphere furnaces, and protective gas furnaces. Its products cater to diverse industries such as aeronautics, automotive, medical, steel manufacturing, and heat treatment contracting, serving clients globally. Metall Technologie Holding's furnaces are utilized for a wide range of applications, including gas and oil quenching, brazing of aluminum and stainless steel, sintering, metal injection molding, tempering, annealing, magnetic annealing and stabilization, aging and stress relieving, as well as low-pressure carburizing, nitriding, and cryogenic treatment.

Sirona Dental Systems is a leading manufacturer of dental technology and laboratory products, providing innovative solutions for dental practices, clinics, and laboratories worldwide. The company offers a diverse range of products, including dental needles, x-ray equipment, implants, removable prosthetics, and various disposable medical devices. Sirona is recognized for its commitment to customer-focused solutions, enhancing the operational efficiency and effectiveness of dental professionals. Through its comprehensive product offerings, the company aims to support the evolving needs of the dental industry.

HemoCue AB is a developer and manufacturer of medical diagnostic products focused on point-of-care testing. The company specializes in microcuvette diagnostic systems that enable the measurement and analysis of key health indicators, such as hemoglobin, glucose, white blood cell count, and urine albumin. These products are designed for use in the diagnosis and management of conditions like anemia, malnutrition, diabetes, and infections. HemoCue's technology ensures that essential blood and urine tests provide lab-quality results quickly and easily, making them accessible for use by healthcare providers in various settings. By prioritizing accuracy and precision, HemoCue aims to enhance patient care and facilitate effective monitoring and evaluation of health conditions.

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.